HRP20161667T1 - Upotreba pidotimoida u liječenju atopičnog dermatitisa - Google Patents
Upotreba pidotimoida u liječenju atopičnog dermatitisa Download PDFInfo
- Publication number
- HRP20161667T1 HRP20161667T1 HRP20161667TT HRP20161667T HRP20161667T1 HR P20161667 T1 HRP20161667 T1 HR P20161667T1 HR P20161667T T HRP20161667T T HR P20161667TT HR P20161667 T HRP20161667 T HR P20161667T HR P20161667 T1 HRP20161667 T1 HR P20161667T1
- Authority
- HR
- Croatia
- Prior art keywords
- pidotimod
- intended
- acceptable salt
- physiologically acceptable
- accordance
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title claims 15
- 229960001163 pidotimod Drugs 0.000 title claims 15
- 206010012438 Dermatitis atopic Diseases 0.000 title claims 2
- 201000008937 atopic dermatitis Diseases 0.000 title claims 2
- 150000003839 salts Chemical class 0.000 claims 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 235000019155 vitamin A Nutrition 0.000 claims 2
- 239000011719 vitamin A Substances 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940045997 vitamin a Drugs 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims 1
- 229960005339 acitretin Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 229960002916 adapalene Drugs 0.000 claims 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 1
- 229960002459 alefacept Drugs 0.000 claims 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 229960002938 bexarotene Drugs 0.000 claims 1
- 229960002882 calcipotriol Drugs 0.000 claims 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims 1
- 229960005084 calcitriol Drugs 0.000 claims 1
- 235000020964 calcitriol Nutrition 0.000 claims 1
- 239000011612 calcitriol Substances 0.000 claims 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960002199 etretinate Drugs 0.000 claims 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229960005280 isotretinoin Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960004907 tacalcitol Drugs 0.000 claims 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229960000565 tazarotene Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (13)
1. Pidotimod ili njegova fiziološki prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju atopičnog dermatitisa.
2. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje na čovjeku.
3. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se primjenjuje topikalno.
4. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se primjenjuje u obliku polučvrste ili tekuće formulacije.
5. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je polučvrsta formulacija krema, gel, mast ili emulzija.
6. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je navedena tekuća formulacija otopina ili suspenzija.
7. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što navedena formulacija ima tež./tež. koncentraciju pidotimoda, ili njegove soli, od 0,1% do 20%, po mogućnosti od 1% do 15%, poželjnije od 5% do 10%.
8. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se primjenjuje u kombinaciji ili vremenski blizu najmanje jednog dodatnog aktivnog principa.
9. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što se navedeni najmanje jedan dodatni aktivni princip bira između imunosupresivnih sredstava, vitamina D i njegovih analoga, spojeva srodnih vitaminu A, kortikosteroida, bioloških tvari.
10. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se navedeno najmanje jedno imunosupresivno sredstvo bira između: metotreksata, azatioprina, ciklosporina, fumarne kiseline, takrolimusa ili pimekrolimusa i kortikosteroida.
11. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se navedeni najmanje jedan analogu vitamina D bira između kalcitriola, kalcipotriola i takalcitola.
12. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se navedeni najmanje jedan spoj srodan vitaminu A bira između retinoida, tretinoina, izotretinoina, etretinata, acitretina, tazarotena, beksarotena i adapalena.
13. Pidotimod, ili njegova fiziološki prihvatljiva sol, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se navedena najmanje jedna biološka tvar bira između alefacepta, etanercepta, te monoklonskih protutijela adalimumaba, infliksimaba, ustekinumaba.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12812220.7A EP2934520B1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat atopic dermatitis |
| PCT/EP2012/076086 WO2014094839A1 (en) | 2012-12-19 | 2012-12-19 | Use of pidotimod to treat atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161667T1 true HRP20161667T1 (hr) | 2017-01-27 |
Family
ID=47520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161667TT HRP20161667T1 (hr) | 2012-12-19 | 2016-12-07 | Upotreba pidotimoida u liječenju atopičnog dermatitisa |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20150352081A1 (hr) |
| EP (1) | EP2934520B1 (hr) |
| JP (1) | JP6058156B2 (hr) |
| KR (1) | KR20150095772A (hr) |
| CN (1) | CN104797254B (hr) |
| AU (1) | AU2012396941A1 (hr) |
| BR (1) | BR112015011394A2 (hr) |
| CA (1) | CA2889388A1 (hr) |
| CY (1) | CY1118633T1 (hr) |
| DK (1) | DK2934520T3 (hr) |
| EA (1) | EA201591184A1 (hr) |
| EC (1) | ECSP15025570A (hr) |
| ES (1) | ES2615748T3 (hr) |
| HK (1) | HK1210938A1 (hr) |
| HR (1) | HRP20161667T1 (hr) |
| HU (1) | HUE030408T2 (hr) |
| IL (1) | IL239292A0 (hr) |
| LT (1) | LT2934520T (hr) |
| MA (1) | MA38156B1 (hr) |
| ME (1) | ME02559B (hr) |
| MX (1) | MX2015008129A (hr) |
| PH (1) | PH12015501211A1 (hr) |
| PL (1) | PL2934520T3 (hr) |
| PT (1) | PT2934520T (hr) |
| RS (1) | RS55424B1 (hr) |
| SG (1) | SG11201503281QA (hr) |
| SI (1) | SI2934520T1 (hr) |
| SM (1) | SMT201700071B (hr) |
| TN (1) | TN2015000159A1 (hr) |
| UY (1) | UY35197A (hr) |
| WO (1) | WO2014094839A1 (hr) |
| ZA (1) | ZA201502983B (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (en) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod for use in the treatment of inflammation-associated diseases |
| EP3754806A1 (en) | 2019-06-19 | 2020-12-23 | UTC Fire & Security EMEA BVBA | Power supply device |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US20050123536A1 (en) * | 2001-11-20 | 2005-06-09 | Che-Leung Law | Treatment of immunological disorders using anti-dc30 antibodies |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
-
2012
- 2012-12-19 MA MA38156A patent/MA38156B1/fr unknown
- 2012-12-19 HU HUE12812220A patent/HUE030408T2/en unknown
- 2012-12-19 JP JP2015548220A patent/JP6058156B2/ja not_active Expired - Fee Related
- 2012-12-19 EA EA201591184A patent/EA201591184A1/ru unknown
- 2012-12-19 WO PCT/EP2012/076086 patent/WO2014094839A1/en active Application Filing
- 2012-12-19 LT LTEP12812220.7T patent/LT2934520T/lt unknown
- 2012-12-19 KR KR1020157018214A patent/KR20150095772A/ko not_active Application Discontinuation
- 2012-12-19 SI SI201230863A patent/SI2934520T1/sl unknown
- 2012-12-19 CA CA2889388A patent/CA2889388A1/en not_active Abandoned
- 2012-12-19 US US14/652,472 patent/US20150352081A1/en not_active Abandoned
- 2012-12-19 MX MX2015008129A patent/MX2015008129A/es unknown
- 2012-12-19 BR BR112015011394A patent/BR112015011394A2/pt not_active IP Right Cessation
- 2012-12-19 CN CN201280077173.2A patent/CN104797254B/zh active Active
- 2012-12-19 ME MEP-2016-275A patent/ME02559B/me unknown
- 2012-12-19 PL PL12812220T patent/PL2934520T3/pl unknown
- 2012-12-19 EP EP12812220.7A patent/EP2934520B1/en active Active
- 2012-12-19 AU AU2012396941A patent/AU2012396941A1/en not_active Abandoned
- 2012-12-19 DK DK12812220.7T patent/DK2934520T3/en active
- 2012-12-19 PT PT128122207T patent/PT2934520T/pt unknown
- 2012-12-19 SG SG11201503281QA patent/SG11201503281QA/en unknown
- 2012-12-19 ES ES12812220.7T patent/ES2615748T3/es active Active
- 2012-12-19 RS RS20161045A patent/RS55424B1/sr unknown
-
2013
- 2013-12-17 UY UY0001035197A patent/UY35197A/es not_active Application Discontinuation
-
2015
- 2015-04-24 TN TNP2015000159A patent/TN2015000159A1/fr unknown
- 2015-04-30 ZA ZA2015/02983A patent/ZA201502983B/en unknown
- 2015-05-29 PH PH12015501211A patent/PH12015501211A1/en unknown
- 2015-06-08 IL IL239292A patent/IL239292A0/en unknown
- 2015-06-16 EC ECIEPI201525570A patent/ECSP15025570A/es unknown
- 2015-11-26 HK HK15111636.0A patent/HK1210938A1/xx not_active IP Right Cessation
-
2016
- 2016-12-07 HR HRP20161667TT patent/HRP20161667T1/hr unknown
-
2017
- 2017-01-30 SM SM201700071T patent/SMT201700071B/it unknown
- 2017-02-14 CY CY20171100199T patent/CY1118633T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201250T1 (hr) | Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze | |
| HRP20161666T1 (hr) | Upotreba pidotimoda u liječenju psorijaze | |
| BR112016022159B8 (pt) | Pó e método para melhorar a aplicação tópica de um agente de benefício ácido | |
| BR112014030820A2 (pt) | formulação de anticorpos | |
| JP2018526325A5 (hr) | ||
| HRP20161667T1 (hr) | Upotreba pidotimoida u liječenju atopičnog dermatitisa | |
| BR112016022607B8 (pt) | Pó e método para aprimorar a aplicação tópica de minoxidil | |
| MA43918A (fr) | Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31 | |
| BR112014000839A2 (pt) | veículo de movimento holonômico para deslocamento em superfícies não niveladas | |
| AR086651A1 (es) | Dentifrico de ion metalico con bajo contenido de agua | |
| UA114615C2 (uk) | Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти | |
| HRP20120915T1 (hr) | Upotreba kitozana u lijeäśenju upalnih bolesti noktiju | |
| BR112014015117A8 (pt) | solução de pulverização agroquímica, formulação agroquímica e método de reduzir a deriva de pulverização de uma solução de pulverização agroquímica após pulverizar com um aparelho de pulverização | |
| WO2016020755A3 (en) | Systems and methods for releasing chlorine dioxide | |
| AR085076A1 (es) | Composiciones agricolas que contienen emulsiones de aceite en agua | |
| RU2012137904A (ru) | Дерматологическая, фармацевтическая композиция, пригодная для олигонуклеотидов | |
| GB201103748D0 (en) | Treatment method | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
| BR112015001919A2 (pt) | método de proteger uma substância ativa a partir da degradação durante peletização de uma ração ou concentrado contendo a substância ativa | |
| BR112014026596A2 (pt) | composição pesticida sinérgica | |
| JP2015522054A5 (hr) | ||
| WO2014007887A3 (en) | Aromatic esters for controlling agricultural spray drift | |
| HRP20161318T1 (hr) | Farmaceutski pripravak koji sadržava fosfolipid | |
| PE18796A1 (es) | Preparacion farmaceutica de cefixima | |
| AR089831A1 (es) | Una composicion y un metodo para tratar sustratos |